Latest research on Salbutamol

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Latest findings

If the distress were found to be due to a respiratory problem, Albuterol would be administered by aerosol. [source, 2016]
In the ED, he was given Albuterol and Atrovent with minimal improvement. [source, 2016]
In the ED, the patient was started on continuous Albuterol nebulizers and given a loading dose of terbutaline. [source, 2016]
The absence of wheezing on exam made him question the diagnosis of reactive airway disease, and he recommended discontinuing the Albuterol for concern of causing airway collapse in patients with bronchomalacia. [source, 2016]
Now several different types of inhaled beta-2 adrenergic agonists are available in clinical practice; short-acting beta-2 agonists (SABA) like Salbutamol, LABA like Salmeterol or formoterol, and ultra-LABA like indacaterol. [source, 2016]
MDI Albuterol was delivered by chamber and facemask to seventeen subjects who underwent pre and post bronchodilator response testing during infant pulmonary function testing. [source, 2016]
The inclusion criteria, with reference to asthma diagnosis criterions of Global Initiative for Asthma including a history of variable respiratory symptoms and confirmed variable expiratory airflow limitation21 were: (1) age 10–12 years; (2) a diagnosis of asthma; (3) use of asthma medication (β2-agonists, corticosteroids, leukotriene antagonists, and/or combination formulation of long acting β2-agonists and corticosteroids) during the past month; (4) dyspnoea, chest tightness and/or wheezing during the past month; and (5) reversible airflow limitation measured during the past year as measured by a 10% increase in forced expiratory volume in 1 s (FEV1) 15 min after inhalation of 0.2 mg Salbutamol per 10 kg body mass (maximum 0.8 mg). [source, 2016]
Likewise, other doctors later involved in the infant’s care should have taken into account the fact that he had wheezing that did not respond to Albuterol, feeding intolerance, and overall did worse than his twin sister. [source, 2016]
After baseline evaluation, spirometry was repeated 15 min after the subjects had inhaled 400 micrograms of Salbutamol as previously reported [22]. [source, 2016]
Five studies evaluated inhaled beta-agonist therapy with salbutamol (International Nonproprietary Name), also known as Albuterol (United States Adopted Name) [17–21]. [source, 2016]